Nuvation Bio Inc.

1.77
-0.05 (-2.75%)
At close: Mar 31, 2025, 3:59 PM
1.74
-1.97%
After-hours: Mar 31, 2025, 04:11 PM EDT

Company Description

Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology.

The company's lead product candidate is NUV-422, a small molecule inhibitor targeting cyclin-dependent kinase (CDK)2, CDK4, and CDK6.

It is also developing NUV-868, a selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation; NUV-569, a differentiated oral small molecule selective inhibitor of the Wee1 kinase for DNA damage repair; NUV-1182, an adenosine receptor inhibitor; and drug-drug conjugate (DDC) platform that focuses on targeting an inhibitor of poly ADP ribose polymerase (PARP) to anti-cancer warheads of existing drugs, as well as PARP inhibitor to address ER+ breast and ovarian cancer.

The company was formerly known as RePharmation Inc. and changed its name to Nuvation Bio Inc. in April 2019.

Nuvation Bio Inc. was founded in 2018 and is headquartered in New York, New York.

Nuvation Bio Inc.
Nuvation Bio Inc. logo
Country United States
IPO Date Aug 26, 2020
Industry Biotechnology
Sector Healthcare
Employees 220
CEO Dr. David T. Hung M.D.

Contact Details

Address:
1500 Broadway
New York, New York
United States
Website https://www.nuvationbio.com

Stock Details

Ticker Symbol NUVB
Exchange NYSE
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001811063
CUSIP Number 67080N101
ISIN Number US67080N1019
Employer ID 85-0862255
SIC Code 2834

Key Executives

Name Position
Dr. David T. Hung M.D. Founder, President, Chief Executive Officer & Chairman
Philippe Sauvage Chief Financial Officer & Principal Financial Officer
Stacy Markel Chief People Officer
Colleen Sjogren Chief Commercial Officer
Dr. David Liu M.D., Ph.D. Chief Medical Officer
Dr. David C. Hanley Ph.D. Chief Technical Operations Officer
Dr. Gary Hattersley Ph.D. Chief Scientific Officer
Kerry A. Wentworth Chief Regulatory Officer
Moses Makunje CPA Vice President of Finance and Principal Accounting & Financial Officer
Stephen Dang Vice President of Legal & Secretary

Latest SEC Filings

Date Type Title
Mar 25, 2025 8-K Current Report
Mar 06, 2025 S-3ASR Automatic shelf registration statement of securiti...
Mar 06, 2025 10-K Annual Report
Mar 06, 2025 8-K Current Report
Mar 05, 2025 8-K Current Report
Mar 04, 2025 4 Filing
Mar 04, 2025 4 Filing
Mar 04, 2025 4 Filing
Mar 04, 2025 4 Filing
Mar 04, 2025 4 Filing